Schedule 13G ownership disclosure

CIDARA THERAPEUTICS INC

Common Stock, $0.0001 par value · CUSIP: 171757206

Event date: 2025-06-30

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Vivo Opportunity Fund Holdings, L.P.

    Shares: 1,175,796.00 · Class: 4.6%

  • Vivo Opportunity, LLC

    Shares: 1,175,796.00 · Class: 4.6%

  • Vivo Opportunity Cayman Fund, L.P.

    Shares: 135,629.00 · Class: 0.5%

  • Vivo Opportunity Cayman, LLC

    Shares: 135,629.00 · Class: 0.5%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001213900-25-075186
Form type
SCHEDULE 13G/A
Filer
Cidara Therapeutics, Inc.
CIK
CIK 1610618
Filed
Aug 12, 2025
Reporting period
Jun 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub